Effects of sub-chronic oral exposure to pyrogenic synthetic amorphous silica (NM-203) in male and female Sprague-Dawley rats: focus on reproductive systems.


Journal

Reproductive toxicology (Elmsford, N.Y.)
ISSN: 1873-1708
Titre abrégé: Reprod Toxicol
Pays: United States
ID NLM: 8803591

Informations de publication

Date de publication:
10 2021
Historique:
received: 15 12 2020
revised: 28 07 2021
accepted: 04 08 2021
pubmed: 12 8 2021
medline: 4 3 2022
entrez: 11 8 2021
Statut: ppublish

Résumé

Synthetic amorphous silica (SAS) consists of agglomerates and aggregates of primary particles in the nanorange (<100 nm) and it is the E551 authorized food additive. The potential risks for human health associated to dietary exposure to SAS are not completely assessed; in particular, data on male and female reproductive systems are lacking. A 90-day oral toxicity study with pyrogenic SAS nanomaterial NM-203 was carried out on the basis of the OECD test guideline 408 in the frame of the NANoREG project. Adult Sprague-Dawley rats of both sexes were orally treated for 90 days with 0, 2, 5, 10, 20 and 50 mg SAS/kg bw per day. Dose levels were selected to be as close as possible to the expected human exposure to food additive E551. The present paper provides specific information on potential effects on male and female reproductive systems, through the evaluation of serum biomarkers, sperm count, histopathological analysis of testis, epididymis, ovary and uterus and real-time PCR on uterus; potential genotoxic alterations were evaluated by comet assay on testis, sperm and ovary. NM-203 did not induce histophatological and genotoxic effects in male reproductive system. In female rats, ovary is not target of NM-203 and only tissue-specific effects on uterus were recorded up to 10 mg/kg bw per day. To our best knowledge, this is the first study providing data on male and female reproductive systems after long-term, repeated oral exposure at dose levels close to dietary human exposure, which identifies a limited concern only for female reproductive health.

Identifiants

pubmed: 34380069
pii: S0890-6238(21)00122-2
doi: 10.1016/j.reprotox.2021.08.001
pii:
doi:

Substances chimiques

Ki-67 Antigen 0
Testosterone 3XMK78S47O
Estradiol 4TI98Z838E
Silicon Dioxide 7631-86-9

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

17-24

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Auteurs

Roberta Tassinari (R)

Center for Gender-Specific Medicine, Istituto Superiore di Sanità (ISS), Viale Regina Elena 299, Rome, Italy.

Eugenia Cordelli (E)

Health Protection Technology Division, Italian National Agency for New Technologies, Energy and Sustainable Economic Development (ENEA) Rome, Italy.

Patrizia Eleuteri (P)

Health Protection Technology Division, Italian National Agency for New Technologies, Energy and Sustainable Economic Development (ENEA) Rome, Italy.

Paola Villani (P)

Health Protection Technology Division, Italian National Agency for New Technologies, Energy and Sustainable Economic Development (ENEA) Rome, Italy.

Francesca Pacchierotti (F)

Health Protection Technology Division, Italian National Agency for New Technologies, Energy and Sustainable Economic Development (ENEA) Rome, Italy.

Laura Narciso (L)

Center for Gender-Specific Medicine, Istituto Superiore di Sanità (ISS), Viale Regina Elena 299, Rome, Italy; Environment and Health Department, Italy.

Sabrina Tait (S)

Center for Gender-Specific Medicine, Istituto Superiore di Sanità (ISS), Viale Regina Elena 299, Rome, Italy.

Mauro Valeri (M)

Experimental Animal Welfare Sector, Italy.

Andrea Martinelli (A)

Experimental Animal Welfare Sector, Italy.

Gabriella Di Felice (G)

National Center for Drug Research and Evaluation, Istituto Superiore di Sanità (ISS), Viale Regina Elena 299, Rome, Italy.

Cinzia Butteroni (C)

National Center for Drug Research and Evaluation, Istituto Superiore di Sanità (ISS), Viale Regina Elena 299, Rome, Italy.

Bianca Barletta (B)

National Center for Drug Research and Evaluation, Istituto Superiore di Sanità (ISS), Viale Regina Elena 299, Rome, Italy.

Silvia Corinti (S)

National Center for Drug Research and Evaluation, Istituto Superiore di Sanità (ISS), Viale Regina Elena 299, Rome, Italy.

Gabriele Lori (G)

Center for Gender-Specific Medicine, Istituto Superiore di Sanità (ISS), Viale Regina Elena 299, Rome, Italy; Università Degli Studi di Roma Tre, Science Department, Viale Guglielmo Marconi 446, Rome, Italy.

Francesca Maranghi (F)

Center for Gender-Specific Medicine, Istituto Superiore di Sanità (ISS), Viale Regina Elena 299, Rome, Italy. Electronic address: francesca.maranghi@iss.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH